The Anteotech Ltd (ASX: ADO) share price is up 18.75% in late afternoon trading, after initially leaping by nearly 23% this morning. The surge in the Anteotech share price comes on the heels of the company’s announcement to the ASX just after today’s market open. The announcement revealed progress with Anteotech’s high sensitivity COVID-19 antigen rapid test moving toward full commercialisation.
Year to date, the Anteotech share price is now up 90%. That compares to an 11% loss for the All Ordinaries Index (ASX: XAO).
What does Anteotech do?
Anteotech is a surface chemistry company holding IP rights over its core technology product groups. Those are AnteoCoat, AnteoBind and AnteoRelease. The company seeks to solve global industry problems through value-added solutions for its clients, including in the diagnostics, life sciences and energy markets.
Anteotech shares first began trading on the ASX in April 2000.
What’s moving the Anteotech share price?
This morning Anteotech announced it completed the second phase of the development of its COVID-19 high sensitivity antigen test, ‘design verification’, earlier than forecast. The company is now progressing to the third phase of development, ‘design validation’. This phase includes clinical trials to gain regulatory approval.
Anteotech also announced it will roll out its stand alone COVID-19 antigen first to meet urgent demand needs. It will roll out its COVID-19 Flu A / Flu B multiplex test in a second stage later in 2020.
Should clinical trials for the COVID-19 stand alone tests prove successful, the company plans to apply for regulatory approval in Australia and the United States simultaneously. Anteotech estimates that the trials and subsequent approval process will take 5 to 8 months to complete.
Addressing the progress, Anteotech’s CEO, Derek Thomson, said:
We are very pleased with the progress we are making on the COVID-19 antigen Flu A / Flu B test development. We believe we have a proven working COVID-19 test with sensitivity far higher than we originally anticipated and this provides us with confidence that we can make a significant contribution to the fight against COVID-19. Our development program is on track and I thank the Life Sciences team for their continued commitment to this very important project.
Anteotech is currently in discussions with the Therapeutic Goods Administration to determine the precise requirements for the clinical trial in the Australian market.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Big 4 ASX banks lower in share market selloff
- How to protect your super in an ASX market crash
- Why you should use the market sell-off to buy these ASX stocks
- Correction or crash for ASX 200 shares?
- 2 ASX ETFs that can solve your income needs
Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Anteotech (ASX:ADO) share price rockets 19% on COVID test announcement appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2GDlfGN
Leave a Reply